Matches in DBpedia 2014 for { ?s ?p Zanamivir INN /zəˈnæmɨvɪər/ is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. Later on in 2006 it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Zanamivir abstract "Zanamivir INN /zəˈnæmɨvɪər/ is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. Later on in 2006 it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed. It is currently marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.".